The administrative support of UWCCC provides the focal point for achieving """"""""centerness,"""""""" the integration that is the hallmark of a successful Cancer Center. This nebulous attribute is essential in our institution where depth and breadth of science abound. The challenge is to provide the resources and atmosphere that will induce investigators to look past their traditional departmental silos, focus their expertise on cancer and take advantage of the opportunities for collaborative research that are essential for translation from discovery to application. The leaders of the UWCCC are responsible for creating the resources and collegial opportunities that support this philosophy and the staff of the UWCCC are responsible for creating the atmosphere that attracts investigators and maintains their participation. Therefore UWCCC Administration provides the support necessary for the UWCCC to achieve its mission in the forthcoming five years. The three highest goals of the UWCCC, now and for the future, are: 1) to conduct the highest quality research into the origins and control of cancer;2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner. The total budget for the administration of the Cancer Center is $3,188,541. This proposal requests support for 14.8% of the administration operating budget. The rest of the operating budget is supported by institutional support and philanthropic dollars.

Public Health Relevance

UWCCC Administration provides the support necessary for the UWCCC to achieve its mission in the forthcoming five years. The three highest goals of the UWCCC are: 1) to conduct the highest quality research into the origins and control of cancer;2) to translate these research findings to evaluation in the clinic through well designed clinical trials with corresponding biologic endpoints whenever possible;and 3) to provide the best care possible to all cancer patients by carefully integrating high quality cutting edge care with clinical research in a compassionate and individualized manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762782
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$336,110
Indirect Cost
$59,442
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Deming, Dustin A (2018) Tailoring the colorectal cancer disease assessment to the treatment strategy. Gut 67:996-997
Ferreira, Carolina A; Ni, Dalong; Rosenkrans, Zachary T et al. (2018) Scavenging of reactive oxygen and nitrogen species with nanomaterials. Nano Res 11:4955-4984
Ehlerding, Emily B; Ferreira, Carolina A; Aluicio-Sarduy, Eduardo et al. (2018) 86/90Y-Based Theranostics Targeting Angiogenesis in a Murine Breast Cancer Model. Mol Pharm 15:2606-2613
Ehlerding, Emily B; Lan, Xiaoli; Cai, Weibo (2018) Predicting PD-1/PD-L1 status in bladder cancer with 18F-FDG PET? Eur J Nucl Med Mol Imaging :
Zhang, Fan; Braun, Doug R; Ananiev, Gene E et al. (2018) Biemamides A-E, Inhibitors of the TGF-? Pathway That Block the Epithelial to Mesenchymal Transition. Org Lett 20:5529-5532
Saghiri, Mohammad Ali; Asatourian, Armen; Sheibani, Nader (2018) Angiogenesis and the prevention of alveolar osteitis: a review study. J Korean Assoc Oral Maxillofac Surg 44:93-102
Pandhi, Nancy; Kraft, Sally; Berkson, Stephanie et al. (2018) Developing primary care teams prepared to improve quality: a mixed-methods evaluation and lessons learned from implementing a microsystems approach. BMC Health Serv Res 18:847
Aluicio-Sarduy, Eduardo; Ellison, Paul A; Barnhart, Todd E et al. (2018) PET radiometals for antibody labeling. J Labelled Comp Radiopharm 61:636-651
Slosarek, Erin L; Schuh, Amber L; Pustova, Iryna et al. (2018) Pathogenic TFG Mutations Underlying Hereditary Spastic Paraplegia Impair Secretory Protein Trafficking and Axon Fasciculation. Cell Rep 24:2248-2260
Tomko, Lucas A; Hill, Ryan C; Barrett, Alexander et al. (2018) Targeted matrisome analysis identifies thrombospondin-2 and tenascin-C in aligned collagen stroma from invasive breast carcinoma. Sci Rep 8:12941

Showing the most recent 10 out of 1528 publications